More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US.
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share pric
Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.